
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington - In the treatment of moderate-to-severe atopic dermatitis, pimecrolimus (Elidel) cream 1 percent is less likely than tacrolimus (Protopic) ointment 0.1 percent to be systemically absorbed, said Zoe Draelos, M.D., lead investigator of a blind treatment trial that compared systemic exposure levels of the two topical drugs.